Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

XBRL 30 June 2020 filed with the SEC

September 16, 2020September 16, 2020 Alterity Therapeutics

XBRL 30 June 2020 filed with the SEC

Post navigation

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

Related Posts

Prana Comments on Nature Medicine, PNAS and Journal of Alzheimer’s Disease articles that highlight the Role of Metals in Neurological Diseases

July 17, 2013

Prana to Present at the UBS Australian Healthcare Conference in Sydney and the Australian Life Science Investment Showcase in New York

July 17, 2013

Prana Biotechnology 2018 AGM Presentation

November 16, 2018

Leave a Reply Cancel reply

Your email address will not be published.Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Δ

Recent Posts

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
Presentation of New Biomarker Data at Scientific Congress
XBRL 30 June 2021 filed with the SEC
Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s
Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065